Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Other Non-Current Assets (2020 - 2025)

Purple Biotech has reported Other Non-Current Assets over the past 3 years, most recently at $10000.0 for Q4 2022.

  • Quarterly Other Non-Current Assets fell 93.75% to $10000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $10000.0 through Dec 2022, down 93.75% year-over-year, with the annual reading at $10000.0 for FY2022, 93.75% down from the prior year.
  • Other Non-Current Assets was $10000.0 for Q4 2022 at Purple Biotech, down from $2.6 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $5.0 million in Q3 2021 and troughed at $10000.0 in Q4 2022.
  • The 3-year median for Other Non-Current Assets is $2.7 million (2022), against an average of $2.7 million.
  • Year-over-year, Other Non-Current Assets plummeted 94.79% in 2021 and then fell 13.48% in 2022.
  • A 3-year view of Other Non-Current Assets shows it stood at $3.1 million in 2020, then plummeted by 94.79% to $160000.0 in 2021, then tumbled by 93.75% to $10000.0 in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Other Non-Current Assets are $10000.0 (Q4 2022), $2.6 million (Q3 2022), and $2.6 million (Q2 2022).